LIMN
Liminatus Pharma, Inc.0.7835
+0.0206+2.7%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
21.21MP/E (TTM)
-Basic EPS (TTM)
-0.16Dividend Yield
0%Recent Filings
10-K
FY2025 results
Liminatus Pharma posted FY2025 net loss of $10.2M, up from $3.5M in 2024, driven by $3.0M operating loss on $2.97M G&A while R&D dropped to zero after terminating CAR-T licenses. Q4 saw $7.4M other expenses from litigation settlements and warrant exchanges, yet TDT payable forgiveness added $2.1M gain. Cash dwindled to $338K amid $10M related-party debt conversions into equity during April's SPAC merger. Nasdaq delisting looms. Pre-clinical IBA101 eyes 2026 Phase 1 trials. Litigation drags momentum.
8-K
Quorum drops to one-third
Liminatus Pharma slashed its stockholder quorum requirement from a majority to one-third of voting power, effective February 27, 2026, via Board-approved bylaw amendment. This eases convening meetings. Board targets ratification at next annual meeting; rejection won't undo it under Delaware law. Lower bar aids governance flow.
8-K
Prices $4M offering at $0.29
Liminatus Pharma priced its best-efforts public offering of 8.27M shares (or pre-funded warrants), 5.54M pre-funded warrants, and warrants for 20.72M shares at $0.29 each, closing February 18, 2026, for $3.46M net proceeds. Funds target clinical trials, R&D, sales, marketing, and working capital. Lock-ups bind insiders; warrants expire in five years.
8-K
Settles $7.5M judgment via shares
Liminatus Pharma settled litigation with Clear Street LLC on February 6, 2026, issuing 4 million common shares for the surrender of 805,377 warrants. The deal dismisses lawsuits, including a $7.5M default judgment plus $515K interest from September 2025. Warrants swapped cheaply. No commissions paid.
8-K
Nasdaq bid price deficiency notice
Liminatus Pharma received a Nasdaq notice on January 15, 2026, for failing to maintain a $1 minimum bid price over 30 consecutive business days, violating Listing Rule 5450(a)(1). Shares continue trading as LIMN with 180 days until July 14 to regain compliance via $1 closes for 10 straight days or a reverse split. No assurance of success. Company is working diligently.
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CNTX
Context Therapeutics Inc.
1.10-0.03
CPMV
Mosaic ImmunoEngineering Inc.
0.40+0.00
CYDY
CytoDyn Inc.
0.32+0.02
FATE
Fate Therapeutics, Inc.
1.09-0.03
IMA
ImageneBio, Inc.
6.25+0.08
LRMR
Larimar Therapeutics, Inc.
3.74-0.18
LSTA
Lisata Therapeutics, Inc.
2.05+0.01
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
SLRX
Salarius Pharmaceuticals, Inc.
0.72-0.06